PharmaFocus Today – Page 6 – media

A Milestone in Pediatric Traditional Chinese Medicine Innovation! Jichuan Pharmaceutical’s Pediatric Laxative Granules Fill a Gap

Recently, Jichuan Pharmaceutical’s independently developed Class 1.1 innovative traditional Chinese medicine, Xiaotongbian Granules ( Pediatric Constipation Relief Granules) , officially received marketing approval from the National Medical Products Administration. This product fills the gap in the domestic market for traditional Chinese medicine specifically for children’s constipation , enriches the company’s product portfolio, and enhances its core competitiveness in the pediatric field. 01 Classic prescriptions from renowned doctors benefit a large number of children suffering from constipation Pediatric Constipation Relief Granules are the first innovative traditional Chinese medicine (TCM) drug approved for use in children under the new regulations and guidelines for innovative TCM drugs. It is the first innovative demonstration product in this field , filling a gap in domestic TCM treatments specifically for childhood constipation. The prescription originates from the clinical experience of pediatric expert Chen Yonghui (Capital Children’s Medical Center, Capital Medical University), and clinical trials have verified ...
- Source: drugdu
- 92
- August 10, 2026
Vonoprazan Fumarate Tablets Receive Drug Registration Certificate

On August 7th, Huahai Pharmaceutical(600521) issued an announcement stating that the company recently received the “Drug Registration Certificate” for vonoprazan fumarate tablets issued by the National Medical Products Administration. The drug is a tablet, with specifications of 20mg and 10mg, and is registered as a Class 4 chemical drug. Vonoprazan fumarate tablets are used for reflux esophagitis and can be used in combination with appropriate antibiotics to eradicate Helicobacter pylori. According to data from Menet.com, the domestic market sales of this drug are projected to reach approximately RMB 282 million in the first quarter of 2026. The company’s R&D investment in the vonoprazan fumarate tablets project is approximately RMB 4.22 million. In the first quarter of 2026, Huahai Pharmaceutical achieved revenue of 2.335 billion yuan and net profit attributable to the parent company of 404 million yuan. https://finance.eastmoney.com/a/202608073835322537.html
- Source: drugdu
- 90
- August 10, 2026
Lenvatinib Mesylate Capsules Receive Drug Registration Certificate

Nanfang Finance News, August 7th – Lu Kang PharmaceuticalThe company announced that it has received a Drug Registration Certificate for Lenvatinib Mesylate Capsules issued by the National Medical Products Administration. This product is used to treat patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy. https://finance.eastmoney.com/a/202608073835336556.html
- Source: drugdu
- 79
- August 10, 2026
Loxoprofen Sodium Patch Receives Drug Registration Certificate

　　Fuyuan Pharmaceutical(601089.SH) announced that it has received a Drug Registration Certificate for Loxoprofen Sodium Patches from the National Medical Products Administration, approving the production of the drug. This drug is used for anti-inflammatory and analgesic purposes for osteoarthritis, muscle pain, and swelling or pain caused by trauma. As of the date of the announcement, the company’s cumulative R&D investment in this drug is RMB 11.7065 million. Sales of Loxoprofen Sodium Patches in China’s three major terminal markets and six major markets are projected to reach approximately RMB 901 million by 2025. https://finance.eastmoney.com/a/202608073835312137.html
- Source: drugdu
- 89
- August 10, 2026
Subsidiary obtains drug registration certificate for injectable multivitamins (12)

　　Wei Xinkang(603676.SH) announced that its wholly-owned subsidiary, Baiyi Pharmaceutical, received approval from the National Medical Products Administration for injectable multivitamins .(12) Drug Registration Certificate. This drug is a Class 4 chemical drug and is considered to have passed the consistency evaluation. In 2025, the sales of this drug in domestic public medical institutions reached RMB 1.601 billion, and the cumulative R&D investment as of the end of July 2026 was RMB 11.3139 million. https://finance.eastmoney.com/a/202608073835199693.html
- Source: drugdu
- 85
- August 10, 2026
its stock price has shrunk by 90% from its issue price, and although it has finally received approval for its first product, the market landscape has already changed.

Kang Le Guardian (i.e., *ST Kang Le)(BJ920575, stock price 4.71 yuan, market value 1.323 billion yuan) has finally ushered in its long-awaited first commercial product. Delivery letter of drug approval certificate published by the National Medical Products Administration on July 30Information shows that the trivalent human papillomavirus vaccine from Health Guard (Kunming) Biotechnology Co., Ltd.(Escherichia coli) has been approved, with approval number S20260057, and approval date July 28. This product covers HPV types 16, 18, and 58. KangLeGuardian had been waiting for this moment for far too long. In March 2023, KangLeGuardian went public on the Beijing Stock Exchange with an issue price of 42 yuan per share, becoming the first HPV stock on the Beijing Stock Exchange. That was also a high point for HPV vaccines —more than 58 million doses were administered in China throughout the year, and HPV vaccines became the vaccine category with the largest increase ...
- Source: drugdu
- 114
- August 4, 2026
China’s first generic tiotropium bromide inhalation spray approved.

China Securities Intelligent Finance News: BrightGene Pharmaceutical(688166) announced on the evening of July 31 that its holding subsidiary, Aitemei (Suzhou) Pharmaceutical Technology Co., Ltd., recently received a Drug Registration Certificate for Tiotropium Bromide Inhalation Spray issued by the National Medical Products Administration. The specification is 60 sprays per bottle, the registration category is chemical drug category 4, and the drug approval number is valid until July 27, 2031. The announcement indicates that this drug is suitable for maintenance treatment of chronic obstructive pulmonary disease (COPD) and related dyspnea, and can reduce acute exacerbations of COPD. The original manufacturer is Boehringer Ingelheim, and currently only the original imported version is available on the market. The National Medical Products Administration (NMPA) website shows that there are currently no generic versions of this drug available in China, making Boehringer Ingelheim the first company to receive approval for its market launch in the country. ...
- Source: drugdu
- 99
- August 4, 2026
Ibrutinib tablets receiving drug registration certificate is considered equivalent to passing the consistency evaluation

China Securities Intelligent Finance Huabang Health(002004) announced on the evening of July 31 that its wholly-owned subsidiary, Chongqing Huabang Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Ibrutinib tablets issued by the National Medical Products Administration. The specifications are 0.14g and 420mg, and the registration category is Class 3 chemical drug, which is regarded as passing the consistency evaluation of generic drug quality and efficacy. The announcement indicates that this drug is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy; patients with chronic lymphocytic leukemia/small lymphocytic lymphoma; patients with Waldenström macroglobulinemia who have received at least one prior therapy, or those who are unsuitable for chemoimmunotherapy .This product is a first-line treatment for patients with Waldenström macroglobulinemia; when used in combination with rituximab, it is suitable for the treatment of patients with Waldenström macroglobulinemia. The company stated that ...
- Source: drugdu
- 91
- August 4, 2026
Isaconazole Sulfate for Injection and Enzalutamide Tablets are expected to be selected in the 12th batch of national centralized procurement

　　China Securities Intelligent Finance News: XuanTai Pharmaceutical(688247) announced on August 4 that its products, Isaconazole Sulfate for Injection and Enzalutamide Tablets, which were jointly developed, are expected to be selected in the 12th batch of national centralized drug procurement. 　　According to the announcement, isaconazole sulfate for injection is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adults; enzalutamide tablets are indicated for the treatment of adult patients with metastatic hormone-sensitive prostate cancer, adult patients with non-metastatic castration-resistant prostate cancer at high risk of metastasis, and adult patients with metastatic castration-resistant prostate cancer who are asymptomatic or have mild symptoms and have not received chemotherapy after failure of androgen deprivation therapy. The proposed winning specifications for isaconazole sulfate for injection are 1 vial/box, and the proposed winning specifications for enzalutamide tablets are 40mg (56 tablets/box) and 80mg (28 tablets/box). The procurement period is from the date of implementation ...
- Source: drugdu
- 101
- August 4, 2026
Leads Biolabs receives IND approval from the National Medical Products Administration for the treatment of metastatic colorectal cancer.

　　On August 3, Leads Biolabs announced on the Hong Kong Stock Exchange that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for its independently developed candidate drug, Verizon (opatidisulfimab, a PD-L1/4-1BB bispecific antibody, LBL-024), for the treatment of metastatic colorectal cancer (mCRC). The approved clinical trial is an open-label, multicenter Phase Ib/II study designed to evaluate the safety and efficacy of Verizon in combination with other drugs for the treatment of mCRC. https://finance.eastmoney.com/a/202608033829221843.html
- Source: drugdu
- 97
- August 3, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.